UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 135

Sortiert nach

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628

2019

Volltextzugriff (PDF)

Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?

The lancet oncology, 2021-10, Vol.22 (10), p.1365-1366

Mano, Max S

2021

Volltextzugriff (PDF)

Borderline indications for ovarian suppression: addressing uncertainties with patients

Future oncology (London, England), 2022-12, Vol.18 (37), p.4111-4118

S Mano, Max

2022

Volltextzugriff (PDF)

Interfaces between medical practice and trading: lessons from the markets

Postgraduate medical journal, 2021-07, Vol.97 (1149), p.411

Mano, Max S

2021

Volltextzugriff (PDF)

Trastuzumab emtansine: a game changer in HER2-positive early breast cancer

Future oncology (London, England), 2020-11, Vol.16 (32), p.2595-2609

Mano, Max

2020

Volltextzugriff (PDF)

If you can't kill the beast, tame it: Tips for surviving WhatsApp® in medical practice

Clinics (São Paulo, Brazil), 2023-01, Vol.78, p.100156-100156, Article 100156

Mano, Max S.

2023

Volltextzugriff (PDF)

Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems

Breast (Edinburgh), 2020-12, Vol.54, p.331-334

Mano, Max S.

2020

Volltextzugriff (PDF)

More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings of the PREDIX HER2 trial

Annals of translational medicine, 2024-02, Vol.12 (1), p.16-16

Mano, Max S

2024

Volltextzugriff (PDF)

Physician leadership in private acquisitions: Styles for all situations

Clinics (São Paulo, Brazil), 2024-01, Vol.79, p.100443, Article 100443

2024

Volltextzugriff (PDF)

Gene expression signatures in early breast cancer: Better together with clinicopathological features

Critical reviews in oncology/hematology, 2022-07, Vol.175, p.103708-103708, Article 103708

2022

Volltextzugriff (PDF)

Implementing multidisciplinary tumor boards in oncology: a narrative review

Future oncology (London, England), 2022-01, Vol.18 (3), p.375-384

2022

Volltextzugriff (PDF)

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

Clinical drug investigation, 2023-09, Vol.43 (9), p.699-706

2023

Volltextzugriff (PDF)

Return to work after breast cancer diagnosis: An observational prospective study in Brazil

Cancer, 2018-12, Vol.124 (24), p.4700-4710

2018

Volltextzugriff (PDF)

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Clinical cancer research, 2023-04, Vol.29 (8), p.1569-1581

2023

Volltextzugriff (PDF)

HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials

Cancer treatment reviews, 2013-10, Vol.39 (6), p.622-631

2013

Volltextzugriff (PDF)

Telehealth, Social Media, Patient Empowerment, and Physician Burnout: Seeking Middle Ground

American Society of Clinical Oncology educational book, 2022-04, Vol.42 (42), p.1-37

2022

Volltextzugriff (PDF)

Reply to R. Freitas-Junior et al

JCO global oncology, 2023-06, Vol.9 (9), p.e2300147-e2300147

2023

Volltextzugriff (PDF)

Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

European radiology, 2022-03, Vol.32 (3), p.1663-1675

2022

Volltextzugriff (PDF)

The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study

Breast (Edinburgh), 2020-12, Vol.54, p.46-51

2020

Volltextzugriff (PDF)

Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil

The oncologist (Dayton, Ohio), 2022-05, Vol.27 (5), p.344-351

2022

Volltextzugriff (PDF)

Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer

Current oncology reports, 2021-05, Vol.23 (5), p.58, Article 58

2021

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(127)

Publikationsform

Artikel
(134)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(79)
Life Sciences & Biomedicine
(76)
Humans
(60)
Oncology
(60)
Female
(43)
Breast Cancer
(38)
Chemotherapy
(27)
Breast Neoplasms - Drug Therapy
(26)
Middle Aged
(22)
Adult
(18)
Treatment Outcome
(15)
Aged
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Trastuzumab
(14)
Obstetrics & Gynecology
(13)
Patients
(13)
Breast Neoplasms - Pathology
(12)
Neoplasm Staging
(12)
Cancer Therapies
(11)
Chemotherapy, Adjuvant
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?

Borderline indications for ovarian suppression: addressing uncertainties with patients

Interfaces between medical practice and trading: lessons from the markets

Trastuzumab emtansine: a game changer in HER2-positive early breast cancer

If you can't kill the beast, tame it: Tips for surviving WhatsApp® in medical practice

Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings of the PREDIX HER2 trial

Physician leadership in private acquisitions: Styles for all situations

Gene expression signatures in early breast cancer: Better together with clinicopathological features

Implementing multidisciplinary tumor boards in oncology: a narrative review

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

Return to work after breast cancer diagnosis: An observational prospective study in Brazil

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials

Telehealth, Social Media, Patient Empowerment, and Physician Burnout: Seeking Middle Ground

Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial

Reply to R. Freitas-Junior et al

Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil

Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer

Suchergebnisse filtern